News & Updates

Show Multimedia Only

4 in 10 adults with chronic pain face mental health woes

18 Mar 2025 by

Chronic pain is accompanied by depression and anxiety in 40 percent of adults, according to the results of a meta-analysis.

4 in 10 adults with chronic pain face mental health woes

18 Mar 2025

$Abaloparatide helps prevent fractures in most vulnerable postmenopausal women$

Abaloparatide helps prevent fractures in most vulnerable postmenopausal women

17 Mar 2025 by

Treatment with abaloparatide appears to reduce the incidence of fractures as well as improve bone mineral density (BMD) in the subgroup of postmenopausal women at highest risk of fracture, according to a post hoc analysis of the ACTIVE* study.

Abaloparatide helps prevent fractures in most vulnerable postmenopausal women

17 Mar 2025

Wearable device improves fatigue, life quality in SSc patients

15 Mar 2025 by

Use of the Apollo wearable for 1 month leads to improvements in fatigue and Raynaud phenomenon (RP) symptoms in patients with systemic sclerosis (SSc), according to a pilot study.

Wearable device improves fatigue, life quality in SSc patients

15 Mar 2025

Original New Drug Application Approvals by US FDA (16-28 February 2025)

14 Mar 2025

New drug applications approved by US FDA as of 16-28 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-28 February 2025)

14 Mar 2025

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

07 Mar 2025 by

The attainment of remission in EGPA is durable whether treated with benralizumab for 2 years or switched to benralizumab after 52 weeks of mepolizumab treatment, with additional merits observed among those who switched, as indicated in the OLE of MANDARA

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

07 Mar 2025

TNFi eases TMJ inflammation in patients with JIA

27 Feb 2025

Treatment with tumour necrosis factor inhibitor (TNFi) can reduce the orofacial signs, symptoms, and MRI-derived inflammation score in patients with juvenile idiopathic arthritis (JIA)-related temporomandibular joint (TMJ) arthritis, a study has shown.

TNFi eases TMJ inflammation in patients with JIA

27 Feb 2025

Obesity impacts symptom severity, prednisone dosing in PMR

27 Feb 2025

Obesity appears to have an impact on both symptom severity and the use of prednisone in patients with polymyalgia rheumatica (PMR), suggests a study. This is potentially driven by subjective pain perception rather than increased inflammation.

Obesity impacts symptom severity, prednisone dosing in PMR

27 Feb 2025

Upper extremity-related disabilities in early RA increase after 2 years

26 Feb 2025

Disability related to the upper extremities (UEs) in early rheumatoid arthritis (RA) is significantly decreased in the first 6 months, but this tends to significantly rise after 2 years, reports a study.

Upper extremity-related disabilities in early RA increase after 2 years

26 Feb 2025

Use of anti–IL-5 therapy in a patient with T2 inflammation–driven CRSwNP, HES, and asthma in a multidisciplinary clinic

26 Feb 2025 by

A 70-year-old female has a history of adult-onset asthma managed with a moderate-dose budesonide/formoterol inhaler. In 2019, she presented with skin rash and neuropathy (numbness). Complete blood counts showed elevated absolute eosinophil, peaking at 6,000 cells/μL. In conjunction with skin biopsy and nerve conduction studies, the diagnosis of hypereosinophilic syn¬drome (HES) was made.

Use of anti–IL-5 therapy in a patient with T2 inflammation–driven CRSwNP, HES, and asthma in a multidisciplinary clinic

26 Feb 2025

News & Updates

Filter by Specialty:

Specialty:

4 in 10 adults with chronic pain face mental health woes

4 in 10 adults with chronic pain face mental health woes

Abaloparatide helps prevent fractures in most vulnerable postmenopausal women

Abaloparatide helps prevent fractures in most vulnerable postmenopausal women

Wearable device improves fatigue, life quality in SSc patients

Wearable device improves fatigue, life quality in SSc patients

Original New Drug Application Approvals by US FDA (16-28 February 2025)

Original New Drug Application Approvals by US FDA (16-28 February 2025)

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

TNFi eases TMJ inflammation in patients with JIA

TNFi eases TMJ inflammation in patients with JIA

Obesity impacts symptom severity, prednisone dosing in PMR

Obesity impacts symptom severity, prednisone dosing in PMR

Upper extremity-related disabilities in early RA increase after 2 years

Upper extremity-related disabilities in early RA increase after 2 years

Use of anti–IL-5 therapy in a patient with T2 inflammation–driven CRSwNP, HES, and asthma in a multidisciplinary clinic

Use of anti–IL-5 therapy in a patient with T2 inflammation–driven CRSwNP, HES, and asthma in a multidisciplinary clinic